An oral medication called danegaptide protects against vision-threatening damage in non-proliferative diabetic retinopathy, according to researchers at Trinity and Breye Therapeutics. The treatment targets the leading cause of blindness in working-age adults by repairing the inner blood-retina barrier, offering a potential preventive alternative to frequent eye injections.
Clinical Findings on Danegaptide in Diabetic Retinopathy
Research demonstrates that danegaptide is safe and exhibits early positive biological activity in patients with non-proliferative diabetic retinopathy (NPDR). The most common form of diabetes-related eye disease, NPDR affects a significant portion of the global diabetic population. Matthew Campbell, Chair of Neurovascular Genetics at Trinity and senior author on the paper, stated that managing the condition before irreversible damage occurs has long been limited by the burden of invasive injections. According to Campbell, the data shows that an oral pill can effectively target and repair the inner blood-retina barrier to protect vision in both eyes simultaneously.
Next Steps for Retinal Care and Clinical Trials
The immediate priority for the research team is advancing to randomised phase II clinical trials. These upcoming studies will confirm long-term efficacy and establish optimal dosing schedules for patients. Clinicians currently wait until sight loss is advanced before treating patients with frequent and invasive eye injections. This therapeutic approach represents a major paradigm shift in retinal care by introducing a non-invasive, preventive path forward long before severe vision loss takes hold.
Global Impact and Registry Data
Diabetic retinopathy impacts one-third of people living with diabetes worldwide, with non-proliferative cases making up the majority of diagnoses. Registry data from Ireland indicates a worrying rise in individuals registering as blind due to the condition, underscoring the urgent need for accessible early interventions. Phase II trials will determine whether the oral medication can successfully transition from laboratory findings to standard clinical practice.
Keep reading